SCHEMBL12440753

SCHEMBL12440753

Cc1c(C)c(C)c2c(oc(=O)c3c(C)c(C)c(C)c(C)c32)c1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 14/20 0.37
ESR1 P03372 13/20 0.37
KDM4E B2RXH2 3/20 0.33
GAA P10253 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
ALDH1A1 P00352 2/20 0.32
HTT P42858 2/20 0.32
ALDH2 P05091 1/20 0.32
CSNK2A1 P68400 1/20 0.32
NSD2 O96028 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
BLM P54132 1/20 0.32
CASP6 P55212 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GPR35 Q9HC97 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15423096 0.92 ESR2 (0.38) ESR2ESR1KDM4EGAACYP1A2
SCHEMBL31155758 0.84 KDM4E (0.40) ESR2ESR1KDM4EGAACYP1A2
SCHEMBL12558040 0.84 KDM4E (0.40) ESR2ESR1KDM4EGAACYP1A2
SCHEMBL805033 0.78
SCHEMBL12440763 0.76
SCHEMBL14444946 0.75 KDM4E (0.39) ESR2ESR1KDM4EGAACYP1A2
SCHEMBL13840560 0.75 KDM4E (0.40) ESR2ESR1KDM4EGAACYP1A2
SCHEMBL5533645 0.72 KDM4E (0.36) ESR2ESR1KDM4EGAACYP1A2
SCHEMBL17447251 0.72
SCHEMBL14733766 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233523-A1 ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS AMAZENTIS SA (CH) 2023-07-27 US disclosed
US-9962366-B2 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof AMAZENTIS SA (CH) 2018-05-08 US disclosed
US-20180015069-A1 ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS OR PRECURSORS THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2018-01-18 US disclosed
US-9318706-B2 Laminated structure, method for producing same, and electronic element comprising same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-04-19 US disclosed
US-20160000753-A1 Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2016-01-07 US disclosed
US-8895675-B2 Block copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-11-25 US disclosed
US-20140018415-A1 Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof AMAZENTIS SA (CH) 2014-01-16 US disclosed
US-8349997-B2 Method for production of block copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-01-08 US disclosed
US-20110177312-A1 LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-21 US disclosed
US-20100219399-A1 BLOCK COPOLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-02 US disclosed
US-20100133476-A1 POLYMERIC ADSORPTION FILMS AND PROCESSES FOR PRODUCING THESE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 US disclosed
US-20100099823-A1 METHOD FOR PRODUCTION OF BLOCK COPOLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110177312-A1 LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME EPCAM, ITGA1, ITGB1 ESR2 212/4885ESR1 67/4885KDM4E 470/4885
US-20230233523-A1 ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS ATG7, BECN1, ATG4A ESR2 2208/4885ESR1 3562/4885KDM4E 1490/4885
US-20160000753-A1 Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof ATG7, BECN1, ATG4A ESR2 2227/4885ESR1 3604/4885KDM4E 1511/4885
US-20180015069-A1 ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS OR PRECURSORS THEREOF ATG7, BECN1, ATG4A ESR2 2227/4885ESR1 3604/4885KDM4E 1511/4885
US-20140018415-A1 Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof ATG7, BECN1, ATG4A ESR2 2227/4885ESR1 3604/4885KDM4E 1511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.